O&rives. The purpose of this study was to investigate whether I) endothelin-I, a potent vasoconstrictor peptide, is involved in progression of pulmonary hypertension caused by congestive heart failure (CHF); and 2) whether long-term treatment with BQ-IU, an endothelin receptor antagonist, ameliorates pulmonary hypertension caused by CHF.
The severity of congestive heart failure (CHF) often correlates with the degree of elevation of pulmonary artery pressure (1) . Various heart and lung diseases are often accompanied by pulmonary hypertension, and the severity of this pulmonary hypertension is an important determinant of the prognosis of these patients (2) . Although the exact factors that promote pulmonary hypertension in these diseases are unknown, it is Rtwhs. Two weeks postoperatively, CHF accompanied by pulmonary hypertension developed in the rats (CHF rats). EXpression of preproeadothelin-1 mRNA in the lung was markedly higher in tbe CHF rats than in the sham-operated rats, W~~KK that k the kidney did not diler between the two groups. Eadotbelia-I staining on the pulmonary vascular cndotb~lial Klls was IGBK intense in tbe CHF rats. BQ-123 treatment over a 2-WKk period in the CHF rats greatly KdUKd right Venttihr systolic pressure and central venous pressure, but it did not rEect blood pressure or Iefl ventricular cnntractBity (peak positive Brst derivative of left ventricular pressure) in these mts.
Conclrsions. Long-term I@-123 tmahnent greatly ameliorated pulmonary hypertension in the CHF rats. The present study suggests that enduthelis-1 plays an important role in the prqression 01 pulmonary hypertension caased by CHF and that aa endotbelin receptor antagonist may be a new tbenpeutlc agent for CHF-induced pulmonary hypertension.
(J Am Cdl Cadiol1996;28: thought that there are some differences in mechanisms for progression of pulmonary hypertension among patients with heart and lung diseases (2) . Endothelin-I. a potent vasoconstrictor peptide produced by vascular endothelial cells (3) (4) (5) (6) , possesses several properties that promote the development of pulmonary hypertension. First, rndothelin-I contracts isolated pulmonary vessels (6-g) and increases pulmonary vascular resistance (6, 9) . Second, it has a mitogenic effect on vascular smooth muscle cells (5, 6, 10) and fib&lasts (6;ll) that is consistent with a roll: in vascular remodeling, a prominent finding in pulmonary hypertensive stages. In rats with monocrotaline-induced pulmonary hypertension, a model of pulmonary hypertension caused by inflammatory lung dise&, we (8) reported that long-term treatment with an endothelin receptor antagonist significantly inhibited the progression of pulmonary hypertension and p&en&d the thickening of the vascular walls of the pulmonary artery. These ;l735-1097~15.oll PI1 xJ735-1097(!Jb)al33&1 findings suggested that endogenous endothelin-l is involved in the progression of pulmonary hypertension caused by inflammatory lung disease. However. it is not known whether endothelin-l is involved in the progression of pulmonary hypertension caused by CHF or whether long-term treatment with an endothelin receptor antagonist is effective in amclicF rating pulmonary hypertension caused by CHF.
Plasma levels of endothelin-1 were reported to be increased in patients (12) (13) (14) and experimental animals (15.16) with CHF. In rats with CHF. we (16) reported that the heart is one of the origins of elevated plasma endothelin-l, because both messenger ribonucleic acid (mRNA) levels and mature peptide levels are markedly increased in the failing hearts of these rats. However, it is unclear whether the production of endothelin-l in the lungs is altered by CHF and it is not known whether long-term treatment with an endothelin receptor antagonist is effective in ameliorating pulmonary hypertension caused by CHF. Cody et al. (12) reported that plasma endothelin-1 concentration correlates with the extent of pulmonary hypertension in patients with CHF, suggesting that elevated circulating endothelin-1 is related to the change in lung conditions in these patients. However, because the lung is an important organ for eliminating endothelin-1 from the circultiiion (17) . it is not known whether this phenomenon is caused by increased production of endothelin-l in the lungs or decreased elimination of endothelin-1 by the lung. Thus, the measurement of plasma endothelin-l ievzls has limitations for assessing production of endothelin-l in the lung. and there is no report that directly indicates whether or not endothelin-l production in the lung is increased in CHF. A study of the expression of prcproendothelin-1 mRNA in the lung would provide an answer to this question, as would a study of the distribuiion of endothelin-l staining in the lung section. The goal of this study was to investigate whether endothelin-1 is invohred in the progression of pulmonary hypertension caused by CHF in rats and whethei long-term treatment with an endothelin receptor antagonist amelioratg pulmonary hypertension ip these rats. For this purpose., we investigated the expression of preproendoihelin-1 mRNA in the lung of rats with CHF and the effti of long-term administration of BQ-123. an endothelin-A reCeptOr (ETA receptor) antagonist (18) . on pulmonary hypertension in rats with CHF induced by coronary artery ligation. Furthermore.
we .
Methds
Experimental heart failure. The left corona? ant? was ligated in the rat to serve as 1 model of C'HF. Thi\ rtrt (CHF rat) i$ a well cstablishcci model (lU.31) in which prrthnph+ logic changes arc similar ta thow seen in ischcmic heart disease. that is. the most common contemporary cause of heart failure in humans (21) . Left ven'ricular free wall myocardisl infarction was induced ia male Sprague-Dawle! :.n> (weighing 170 to Y10 g) according to thr mcthtd of Pfcffcr ~1 al. (II)). as we (16) have previously described in detail. In brief. each rat was anesthetized with ether. A thoracotomg was performed. the heart was rapidly exteriorized and thr: proxima! portion of the left coronary artery was ligated with a 5-O <ilk suture. Except for coronary artev ligation. sham-operated rats underwent an identical proctdurc.
About 604 of the rats ,*ith myocardial infarction died within the 1st 24 h. the surviving rats were maintained on standard rat chow and water ad libitum for 2 weeks. The study was approved by Universib of Tsukuba and conformed to the "Position of the American Heart Association on Research Animal Use" adopted by the Association in November 19&I.
Seven days postoperatively. myocardial infarction was c-In-!irmed by electrocardiography:
for these experiments ye used only rats habing abnormal Q waves in both limb leads 1 and aVL as these findings have been reported (20) to represent a medium to large infarct size. In a previous study we (16) found that under these conditions. and with electrocardiographic (ECG) assessment congestive heart failure develop in the rats within a few weeks after opcrati,.,. Hemodynamicmea The plasma. and' tissue samples were stored at -80°C for mature endothelin-1 peptide assay and for determination of preproendothclin-l mRNA expression. Some of these rats were used for immunohistochemical study.
Sandwich-enzyme immunoassay to determine plasm .
endothelin-1 levels. Plasma endorhelin-1 concentration was measured by a sandwich-enzyme immunoassay as we (8,16.22) hare previously described. In brief, each blood sample was placed in a chilled tube containing aprotinin (300 kallikreininhibiting U/ml) and EDTA (2 mg/ml) and was centrifuged at 3,000 g for 15 min at 4°C. Sandwich-enzyme immunoassay for endothelin-1 was carried out as previously described by using immobilized mouse monoclonal antibody AwETN40. which recognizes the N-terminal portion of endothelin-1. and peroxidase-labeled rabbit antiendothelin-1. C-terminal peptide (15-21) Fab' (8, 16, 22) . The assay for endothelin-1 did not cross-react with endothelin3 or big-endothelin-1 (crossreactivity <O.l%) (8, 16, 22) .
Northern blot analysis for preproendothelin-1 mRNA in the lung and kidney. Total RNA was prepared from the lung and kidney of sham-operated rats and the CHF rats, by selective precipitation in 3-molfliter lithium chloride and h-mol/liter urea as we (8, 16, 23) have previously described. In brief, total RNA (10 pg/Iane) from the lung and the kidney was separated by formamide/l .l% agarose gel electrophoresis and transferred onto nylon membranes (Hybond N. Amersham, Buckinghamshire, United Kingdom). The membranes were hybridized with a phosphorus-32-labeled complementary deoxyribonucleic acid (cDNA) probe. After hybridization, the filter was finally washed in 0.1 X standard saline citrate/O.l% sodium dodecyl sulfate at 50°C and autoradiographed with intensifying screens at -80°C for 24 h. The prcproendothelin-1 cDNA used as a probe in the present study was a previously described full-length insert of lambda r-endothelin-l-2 (8, 16, 23) that was labeled by random priming with [alphaphosphorus-321 deoxycitidine triphosphate (dCTP) (-3,000 Cilmmol, Amersham). To normalize the preproendothelin-I signals for the loaded amounts and transfer efficiencies, the same membranes were rehybridized wtth beta-actin cDNA probe or ethidium bromide staining of 18s ribosomal RNA as the internal control.
lmmunohistochemical analysis for endothelio-1 staining in the lungs. Tissue endothelin-1 staining (endothelin-l-like immunoreactivity) was studied by using methods we (4,24) have previously described with minor modifications. In brief, after hemodynamic measurement, the lungs were subjected to perfusion fixation with 0.01 mol/liter periodat+0.075 mol/Iiter lysin-2% parafcrmaldehyde solution, and fixed in this solution at 4°C overnight. The specimens were embedded in paraffin wax (melting point! SSOC). The sections were.eut into 3-km thickness and stained immunohistoehemically by using the biotin-streptoavidin-horseradish peroxidase method for, the detection of endothelin-1. Rabbit antiendothelin-1 polyclonal antibody (Peninsula Lab., Inc.) was used as the primary antibody. DeparatIinized sections were incubated with rabbit antiendothelin-I antibody (dilution 1:40(l) a! room temperature. for 3 h. After being washed. the sections were incubated with secondary antibody diluted at l:lUO (biotinylated antirdbbit immunogamma globulin; IBL, Fujioka, Japan) for 30 min, tlen with horseradish peroxidase-conjugated streptavidin dilJ!ed at 1:lOO for 30 min. lmmunoreactive endothelin-1 prod-1;~s were visualized with 0.05% 3,3'-diamino-benzidine-O.O2'% ',:!droperoxide. The slides were counterstained with methyl preen. The specificity of the immunoreuctivity was determined by an absorption test; that is, the consecutive sections were subjected to the same procedure with the use of the supematant of antiendothelin-1 antibody (dilution 1:loO) preabsorbed with synthetic endothelin-1 (20 PmoVliter) at 4°C for overnight.
Erects of continuous BQ-123 infusion for 2 weeks on hemodynamic variables in the CHF rats. To investigate the effects of continuous BQ-123 infusion on the CHF rats, an osmotic minipump (model 2ML2, Alza Co.) was subcutaneously implanted in the CHF rats and sham-operated rats on the day after myocardial infarction. BQ-123, donated by Dr. Masaru Nishikibe (Tsukuba Research Institute, Banyu Pharmaceutical Co., Tsukuba. Japan), was dissolved in saline solution. The osmotic minipumps contained either saline solution ah-e or saline solution and BQ-123. The rats were separated into three groups as follows: group 1. CHF rats receiving continuous BQ-123 infusion (15 mg/rat per day) for 2 weeks, group 2, CHF rats receiving continuous saline infusion for 2 weeks; and group 3, sham-operated rats receiving continuous saline infusion for 2 weeks. Two weeks after the osmotic minipump was implanted, it was extracted under ether anesthesia 24 h before the experiments; that is, the hemodynamic measurements were performed after a 24-h washout period for BQ-123. The hemodynamic variables 'vere measured under pentobarbital anesthesia (50 mg/kg body weight).
Infarct size was measured as previously described (16.19) in both the CHF rats treated with saline solution and the CHF rats treated with BQ-123. In brief, after being weighed, the heart was immersion-lixed in 10% buffered formalin and then cut into four transverse sections from apex to base. These sections were processed in standard fashion and embedded in paraffin. A M.rsson trichrome-stained thin section from each level was projected, and the perimeters of the infarcted and noninfatcted epicardial and endocardial surfaces were traced and digitized. The infarcted portion (the proportion of the infarcted left ventricle) was calculated from these measurements (16.19) .
Statistical analysis. All statistical comparisons were performed by using a statistical package for the Macintosh personal computer (STAT VIEW, version 4.0, Abacus Concepts, Inc.). Differences between data for the CHF and shamoperated rats were assessed by ,an unpaired r test.. One-way analysis of variance followed by Bonferroni's multiple comparison test was used for statistical comparison among the three treatment groups (see Table 2 , Fig. 4 ). Differences were considered significant at p < 0.05. 
Results
Hemodynamic variables and tissue weights. Mean arterial blood pressure. left ventricular peak systolic pressure and left ventricular tdP/dt,,, were significant11 lower m the CHF rats than. in the sham-operated rats (Table 1) . Left ventricular end-diastolic pressure was markedly elevated in the CHF rats (Table l) , and right ventricular systolic, right ventricular end-diastolic and central venous pressures were significantly higher in the CHF rats than in the sham-operated rats (Table  1 ). These data indicate that CHF accompanied by pulmonary hypertension developed in the CHF rats.
The CHF rats weighed !CTS than the sham-operated rats (277 it 8 vs. 307 + 4 g. n = 6, p < 0.05), and their lung weight mass index for body weight was much higher (8.53 + 0.63 vs. 3.90 2 0.14 mg/g, p < O.Ol), suggesting that they had pulmonary congestion. Right ventricular mass index for body weight was signilicantly higher in the CHF rats than in the shamoperated rats (1.17 2 0.09 vs. 0.60 2 0.02 mug, p < 0.01). but left ventrkzvlar mass index for body weight was not different in the two groups (2.31 2 0.08 vs. 2.17 -t 0.06 mglg, p = NS).
Plasma eudothelio-1 level. The plasma endothelin-1 concentralion of the CHF rats was -3.3-fold higher than that of the sham-operated rats (3.89 2 0.49 vs. 1.32 +-0.10 pg/ml. n = 6, p < 0.01).
Expression of preproendothelin-1 mRNA in the lung and kidney, The expression of preproendothelin-1 mRNA in the lung of both the CHF rats and the sham-operated rats was determined by Northern blot analysis. Typical examples of the lung at 2 weeks after operation are shown in Figure 1 . The expression of preproendothelin-1 mRNA in the lung in the CHF rats was much higher than that in the sham-operated rats (Fig. 1) . Densitometric analysis of these blots corrected for the levels of beta-a&n mRNA, which was used as normalization for a constitutively expressed message in the lung. The densitometric ratio of (preproendothelin-1 mRNA)/(beta-actin mRNA) in the lung of the CHF rats was significantly higher than that, in the sham-operated rats (0.38 -C 0.04 vs. 0.15 f 0.02, n =,5, p < 0.01). However. in the kidney, the expression of preproendothelin-1 mRNA did not differ between the two rat groups (Fig. 2) .
Inun~Wchemkal analysii lor endotMn-1 st&i&ia tfie 1~
The typical examples of endothelin-l staining (i.e.. endothelin-l-like immunoreactivity) in the rat lung demonstrated by immunohiiocbemical methods are shown in Figure   3 . The endothelin-1 staining (endothelin-1-like immunoreactivity) appeared brown (Fig. 3) . The vascular endothelium was stained brown. indicating that endothelin-I is dis!ributed in the vascular endothelium of both the sham-operated rats (Fig. 3 . left) and the CHF rats (Fig. 3. right) . Figure 3 shows that the intensity of the endothelin-1 staining (endothelin-l-like immunoreactivity) on the vascular endothelial cells of the pulmonary artery was more intense in the CHF rats than in the shamoperated rats. Results similar to those shown in Figure 3 were observed in six CHF rats and six sham-operated rats. However. the intensity of the endothelin-1 staining on the alveolar macrophages did not differ between the two rat groups (data not shown).
The absorption test showed that the endothelin-l-like immunoreactivity was greatly reduced when the primary antibody was absorbed with synthetic endothelin-1 (20 pmol/liter) (data not shown). indicating that the immunoreactivity was specific for endothelin-I.
Elects of continaous IQ-123 infusion oo hemodyoamic variables and tissue weights. Continuous infusion of BQ-123 (15 mg/rat per day) for 2 weeks caused sigltificant reductions in right ventricular systolic pressure (by 489. Fig. 4. left) . right ventricular end-diastolic pressure (by 49%. Table 2 ) and central venous pressure (by 75%. Fig. 4 . right) in the CHF rats. The expression of preproendothelin-1 mRNA in the kidney of CHF rats did not differ from that of sham-operated rats. kb = kilobase.
Thus, continuous infusion of BQ-123 for 2 weeks greatly ameliorated pulmonary hypertension in the CHF rats. It did not affect mean blood pressure? left ventricular +dP/dt,, or left ventricular end-diastolic pressure in this group (Table 2) . However, because we did not measure cardiac output or blood flow in the aorta, we cannot know how BQ-123 treatme,l: affected the afterlcId of the I& ventricle. The ratio of the weight of the,rigtt ventricle to body weight was signifi!antly higher in the CHE' rats treated with saline solution than in the sham-operated rats treated with saline solution (1.26 -C 0.06 vs. 0.60 t-0.02 mg/g, n = 6, p < 0.01). Long-term BQ-123 Jreatment significantly (p < 0.05) ameliorated right ventricular hypertrophy. The ratio of the weight of the left ventricle to body weight did not differ among three groups; that is. the ratios in the sham-operated rats treated with saline solution, the CHF rats treated with saline solution and the CIiF rats treated with BQ-123 were 2.20 c 0.04, 2.33 ? 0.06 and 2.36 2 0.09 (each n = 6), respectively.
The mean myocardial infarct size in the CHF rats treated with saline solution (49 + 4%) was not different from that in the CHF rats treated with BQ-123 (50 + 5%).
Discussion
Effects of long-term treatment with an entiothelin receptor antagonist on pulmonary hypertension caused by CHF. At 2 weeks after coronary artery ligation, congestive heart failure accompanied by pulmonary hypertension developed in the rats. The expression of preproendothelin-1 mRNA was markedly increased in the lung of the CHF rats and endothelin-1 staining in the vascular endothelial cells of the pulmonary artery was more intense in the CHF rats than in the shamoperated rats. Furthermore, the present study demonstrated for the first time that long-term treatment with BQ-123, an endothelin-A receptor (ETA receptor) antagonist (18) , greatly ameliorated pulmonary hypertension in the CHF rats, suggesting that an endothelin receptor antagonist may be a potential therapeutic agent for pulmonary hypertension caused by CHF. The latter finding is very important because pulmonary hypertension caused by CHF is resistant to many drugs and is often a progressive condition that ultimately leads to right heart failure and death (2) . The present findings suggest that endogenous endothelin-1 greatly contributes to the progression of pulmonary hypertension caused by CHF in rats. It has been reported that endothelin-l-induced vasoconstriction of the pulmonary artery is mainly mediated by endothelin ETA receptors in rats (6, 25, 26) and humans (27) . 12) reported that plasma endothelin-1 concentration correlates with the extent of pulmonary hypertension in patients with CHF, suggesting that elevated circulating endothelin-1 is related to the change in lung conditions in these patients. However, controversy persists regarding the producfon of endothe!io-! in the lung in CHF. Tsutamoto et al. (28) showed that the plasma endothelin-1 level was increased significantly in plasma from the main pulmonary artery to that in the pulmonary capillary wedge region in patients with CHF, whereas Eaton et al. (29) reported the absence of pulmonary endothelin gradient in patients with normal or elevated circulating endothelin. Because the lung is an important organ for eliminating endothelin-1 from the circulation (17), the measurement of plasma endothelin-1 levels has limited ability to assess production of endothelin-1 in the lung. In the present study, our findings are novel in that we have directly demonstrated that the production of endothelin-1 in the lung is increased in CHF. because the expression of preproendothelin-1 mRNA in the lung was greatly increased in the CHF rats. As the expression of preproendothelin-I mRNA in the kidney did not differ between the CHF rats and the sham-operated rats, the increase in endothelin-1 production is a relatively specific phenomenon in the lung of the CHF rats. The present immunohistochemical study also revealed that endothelin-1 staining in 'p < 0.01 vetsus the corresponding value for Sham + salti rats. tp ,< U.01 versus the cqrespondii value for CHF + saline rats. Valu& presented are mean value % SEM. CHF + BQ-123 = CHF rats given continuous RQ-12.3 infusion for 2 weeks, CHF + saline = CHF rats given continuous saline infusion fa 2 wels; Sham + saline = sbm-operakd rats given contimmus saline inhtsion for 2 weeks Other alkviations as in Table 1 .
(mmHg) es N.S. the vascular endothelial cells of the pulmonary artery was more intense in the CHF rats than in the sham-operated rats. Therefore. it is suggested the increased peptide level of endothelin-1 in the pulmonary vascular endothelial cells in the CHF rats is attributed td; the increase in the endothelin-1 gene transcription.
The reason for the enllanced expression 9f preproendothelin-1 mRNA in the lung of ChF rats remains to be elucidated. It has been repotted that the expression of preptuendorhelin-I mRNA was increased by hemodynamic shear stress in alltured vascular endothelial cells (30) and that pure pressure without shear stress or stretch enhanced thf: release of endothelin-1 in cultured human endothelial cells (31). These results suggest that pmduction of endothelin-I in vascular endotbelial ,?eUs may be increased by mechanical factors Therefore, it can be assumed that hem& dynamic overload to the pulmonary vzsc.llar endothelium by pulmonary hypertension causes the increase in the expression of preproendothelin-1 mRNA in the pulmonary vascular endothelium in CHF rats. This argument is in agreement with our finding (32) that elevated levels of circulating plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease were decreased in accordance with amelioration of pulmonary hypertension by sucu5sM sqical repair.
Expressiou of embtbelia-1 in pbnnwy hypertensiw dee tu difemnt eWugies. Plasma endothelin-1 concentration was reported to be elevated in animal models qf pulmonary hypertension caused by lung diseases (i.e.. r;ts with pulmonary hypertension induced by hypoxia [33] or monocrotaline [S] ). In rats with monocrotaline-induced pulmonary hypertension a rat model of pulmonary hypertension caused by inflammatory 1Lng disease, we (34) reported that the intensity of endothebl staininginthepulmonaryarterywassameasthatincontrdrats whereas the intensity of endothelin-1 staining in the alveolar mactupbages was markedly inaead. In patients with pulmonaiy hypertension caused by noninflammatory lung disease or m genie m arteriopatby, Giaid et al. (35) reported that tbe expnzssion of endotbelin-l is increased in the pulmonary vascular ,endothelial ceils.
-!kkctive ekets of IQ-123 00 the pmlnosug circuit to lomrarteIidprrsJrrrwltbont~ectiagthepassiveeom~ neotofpabonagbypehhniaCHF.
Inthisstudy.BQ-I23 affected neither left ventricular +dP/dt,, nor left ventric-SAC-C. Vol. 2X. No. h ENDOTHELlN-I AND PULMONAKY tIYPtiR-tXNSIf)N iXE 1'0 ('HF Nwcmhcr IS. IYYc)h:ISW-S ular end-diastolic pressure. indicating that it did not affect the impaired functron of the left ventriclein the CHF rats. Thus. the administration of BQ-123 for 28 weeks did not affect the condition .of left heart failure in rats with CHF. It has been considered that the pulmonary hypertension seen 'in isolated left heart failure is due. to predominantly passive phenomena caused by elevated left-sided pressures (1) . Neverthclcss. the present study showed that long-term BQ-123 treatment greatly reduced pulmonary artery prcssurc but not systemic artcrial pressure in the CHF rats. Thus. BQ-123 selectively reduced pulmonary artery pressure in the CHF rats. One possible explanation for this finding is that there is a major vasoactive compo nent to pulmonary hypertension seen in left heart failure and endothclin-1 may be a candidate for the component. It has been reported that endothelin-l-induced vasoconstriction in various rat arteries that participate in the regulation of the systemic circulation is mainly mediated by ET,\ receptors (25) and that BQ-123 greatly antagonizes the prcssor effect of exogenously applied endothelin-I in rats (16.18,36) . Thcrcforc, WC consider that the difference between the effects of BQ-123 on pulmonary artery pressure and on systemic pressure may be attributed to the difference in the production of endothelin-I in the vascular endothelium between the pulmonary and systemic circulations in the CHF rats. This consideration is partly supported by the finding that the expression of preproendothelin-1 mRNA in the CHF rats is increased in the lung but not in the kidney.
Our previous study (16) showed that short-term administration of the ETA receptor antagonist BQ-123 did not alter mean blood pressure in the CHF rats. However. Teerlink et al. (37) reported that short-term administration of the ETA/ endothelin-B (ETB) combined receptor antagonist bosentan lowers hlood pressure in rats with CHF due to myocardial infarction. One possible explanation for the discrepancy in short-term effects on systemic blood pressure between BQ-123 and bosentan is that the blockade of both ETA and ETB receptors by hosentan may contribute to its blood pressurelowering effect in CHF rats, because both ET,+mediated and ET&mediated mechanisms for vascular contraction exist in various vessels (625). In the present study, long-term BQ-123 treatment did not affect mean arterial pressure in the CHF rats. However, it is not known whether long-term treatment with ETA/B combined receptor antagonists affects systemic blood pressure of the CHF rats. In patients with severe chronic heart failure (New York Heart Association class III), Kiowski et al. (38) reported that short-term (2-h) infusion of the ETA/u combined receptor antagonist bosentan significantly reduced mean systemic arterial pressure by 7.7% and pulmonary artery pressure by 13.7%. However, there is no report whether long-term treatment (at least 2 to 3 weeks) with endothelin antagonists alters systemic arterial pressure or pulmonary artery pressure in patients with chronic heart failure.
Effects of endothelin receptor antagonists on niyocardial infarct size. This heart failure model-that is, rats Gth myocardial infarction-is well established, and some investigators have reported the effects of endothelin antagonists on this 42) ohs:rved that FR-139317 had no cffcct on infarct size. In the present study. the ET,\ receptor antagonist BQ-123 had no effect on the infarct size. in accordance with the study's finding that longterm (2 weeks) BQ-123 treatment did not affect left ventricular +dP/dt,,, or left ventricular end-diastolic pressure in the CHF rats. The reason for these differences among studies is unclear.
Study limitations. In the present study, treatment with BQ-I23 was started on the day after infarction and continued for 2 weeks. This time period was selected for assessment of the long-term effects of BQ-123 on the pulmonary hypertension caused by CHF, because we (16) have previously found in this modal that at this stage CHF-induced pulmonary hypertension is marked but myocardial hypertrophy of the surviving myocardium in the left ventricle is less markrd. .9t later stages (several months after infarction). we observed (unpublished data) that significant myocardial hypertrophy occurs in this animal. In the present study, BQ-123 treatment over a 2-week period did not affect the impaired function of the left ventricle in the CHF rats despite significant reductions in right ventricular systolic pressure and central venous pressure. Thus, BQ-123 greatly ameliorated right heart failure in the CHF rats without ameiiorating the condition of left heart failure in these rats at this stage. However, because an endnthelin receptor antagonist has been reported to prevent cardiac hypertrophy in vitro (6, 43) and in vivo (6.844) . it remains to be assessed whether longer treatmcnt periods (e.g.. several months) would ameliorate left ventricular remodeling (hypertrophy of cardiac myoqtes in the surviving myccardium, cavity enlargement of the left ventricle, among others) or the left heart failure in the CHF rats.
In the present study, we did not investtgate whether Iongterm BQ-123 treatment affects the preproendothelin-1 mRNA expression or endothelin-l-like immunoreactivity in the lung of CHF rats. Therefore, it is still unclear whether long-term BQ-123 treatment affects the regulation of endothelin-1 production in the lung of CHF rats.
Our previous report (8) indicated that marked thickening of the vascular walls of the pulmonary artery occurred in the rats with pulmonary hypertension caused by inflammatory lung disease due to monocrotaline and that long-term treatment with BQ-123 greatly inhibited this thickening. However, the present study showed slight thickening of the vascular walls of the pulmonary artery in the CHF rats (Fig. 3) ; therefore, it is difficult to assess whether long-term BQ-123 treatment inhibits the thickening of the vascular walls of the pulmonary artery in CHF rats. The CHF rats used in the present study were studied 2 weeks postoperatively; however, we have found (unpublished observation) that the marked thickening of the vasculrrr walls of the pulmonary artery ,occurs in the CHF rats 3 months postoperatively. Therefore. additional study using the CHF rats 3 months postoperatively is required to resolve this question.
In the: present study. right ventricular systolic pressure of the sham-operated rats appeared to be relatively higher than that iri humans. .Because we measured the right ventricular pressure with a fluid-filled system at high heart rates (--330 beatdmin), we consider that the time constant was not sufficient to allow an adequate response, and this may be a redson for the relatively high pressure.
Conclusions. The expression of preproendothelin-I mRNA was greatly increased in the lung of the CHF rats and the endothelin-1 staining in the vascular endothelial cells of the pulmonary artery was more intense in the CHF rats than in the sham-operated rats. Furthermore, continuous infusion of BQ-123 for 2 wczks greatly ameliorated pulmonary hypertension in the CHF rats. Therefore, the present study suggests that endogenous endothelin-1 contributes to the progression of pulmonary hypertension caused by CHF in rats and that an endothelin receptor antagonist may be a new therapeutic agent for pulmonary hypertension caused by CHF.
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